2012 Comment Letters

AACC continually tracks legislative and regulatory issues of importance to clinical laboratories and the clinical laboratory profession. This is a listing of AACC's 2012 comment letters. AACC commented on a wide range of topics to federal and state authorities.

Legislative Issues

AACC joins with the Clinical Laboratory Coalition in opposing additional cuts in laboratory payments 

NOV.29.2012

AACC endorses H.R.6118, the "Taking Essential Steps for Testing Act," which would give CMS more flexibility in assessing penalties for violating the CLIA PT referral provisions 

AUG.01.2012

AACC supports full federal funding for the NIH National Children's Study 

JUL.30.2012

AACC urges legislators to oppose the elimination of funding for the Agency for Healthcare Research and Quality 

JUL.30.2012

AACC joins with the Clinical Laboratory Coalition in seeing the repeal of the forthcoming medical device tax 

JUN.06.2012

AACC opposes inclusion of LDT legislation in FDA user fee legislation 

MAY.21.2012

AACC supports House changes to the de novo process 

MAY.16.2012 

AACC supports Senate changes to the de novo process 

MAY.09.2012

AACC supports congressional involvement regarding the FDA June 2011 RUO/IUO draft guidance 

MAY.01.2012 

AACC joins with the Friends of AHRQ in supporting additional research funding for AHRQ 

MAR.19.2012 

AACC, as part of the DC Principles Coalition, opposes legislation that gives the government a greater role in determining when private sector articles are made free to the public 

MAR.05.2012

AACC supports continued funding for the National Children's Study 

FEB.28.2012

AACC opposes legislation that would eliminate the Patient-Centered Outcomes Research Institute 

FEB.28.2012

AACC seeks answers regarding the impact of congressional legislation on patient access to laboratory developed tests 

FEB.16.2012

AACC and the Clinical Laboratory Coalition opposes proposed cuts in laboratory reimbursement 

FEB.15.2012

AACC supports congressional efforts to streamline the FDA's de novo process 

FEB.02.2012

Regulatory Issues

AACC writes to CMS recommendation revisions to the draft Individualized Quality Control Plan 

OCT.10.2012

AACC writes to the State of Massachusetts urging support for harmonization efforts 

SEP.19.2012

AACC writes to CMS suggesting that most molecular codes remain on the clinical laboratory fee schedule 

SEP.18.2012

AACC urges CMS to consider technology when determining which fee schedule to place the new molecular codes 

AUG.08.2012

AACC wrote to CMS opposing the placement of all molecular codes on a single fee schedule 

JUL.12.2012

AACC provided CMS with input regarding the payment amounts for the new 2013 CPT codes 

JUL.12.2012

AACC provided input to the FDA regarding the design and performance of indwelling continuous blood glucose monitors 

JUN.25.2012

AACC submits comment to CMS regarding March 7, 2012 CMS proposed rule regarding electronic health record incentive payments 

MAY.07.2012

AACC provides input to the Patient-Centered Outcomes Research Institute regarding its research agenda 

MAR.14.2012 

AACC supports the Joint Commission's efforts to reduce inappropriate test utilization>AACC supports the Joint Commission's efforts to reduce inappropriate test utilization 

JAN.20.2012